{"schema_version":"secwatch.filing_event.v1","accession":"0001739410-23-000019","form_type":"8-K","ticker":"RLYB","cik":"0001739410","company_name":"Rallybio Corp","filed_at":"2023-12-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.271083+00:00","generated_at":"2026-06-07T09:54:48.152611+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Rallybio reveals Phase 1 MAD data for RLYB116: >93% free C5 reduction at 100 mg weekly; cash runway extended to 3Q 2025","bullets":["100 mg weekly dose of RLYB116 achieved >93% mean reduction in free C5 at Day 29; >99% reduction 24h post-first dose.","RLYB116 half-life >300 hours; low inter-subject variability; all adverse events mild, most common injection-site reaction (60% in 100mg cohort).","Company deprioritizes Phase 2 start in gMG, focusing on manufacturing to improve tolerability and widen indications.","Cash runway guidance updated: current resources expected to fund operations into Q3 2025.","RLYB212 for FNAIT continues as lead program; near-term RLYB116 investments directed to process improvements."],"urls":{"canonical":"https://secwatch.observer/filing/0001739410-23-000019","json":"https://secwatch.observer/filing/0001739410-23-000019.json","markdown":"https://secwatch.observer/filing/0001739410-23-000019.md","text":"https://secwatch.observer/filing/0001739410-23-000019.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1739410/000173941023000019/0001739410-23-000019-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1739410/000173941023000019/rlyb-20231220.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T09:54:48.152611+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}